Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition for the treatment of ocular neovascularisation

A new blood vessel and composition technology, which can be used in drug combination, drug delivery, pharmaceutical formulation and other directions, and can solve problems such as systemic adverse reactions

Pending Publication Date: 2021-10-19
NOVALIQ GMBH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, systemic administration of biologically active substances always carries the risk of significant systemic adverse effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the treatment of ocular neovascularisation
  • Pharmaceutical composition for the treatment of ocular neovascularisation
  • Pharmaceutical composition for the treatment of ocular neovascularisation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0048] Preferred embodiments of the method according to this aspect of the invention are:

[0049] CLAIMS 1. A method of treating ocular neovascularization comprising administering to the eye of a subject in need thereof a pharmaceutical composition comprising tacrolimus and a semifluorinated alkane.

[0050] 2. The method according to item 1, wherein the ocular neovascularization is retinal and / or choroidal neovascularization.

[0051] 3. The method according to any one of items 1 or 2, wherein said ocular neovascularization is caused by or associated with a disease selected from the group consisting of age-related macular degeneration, diabetic macular edema, central Retinal vein occlusion, retinopathy, branch retinal vein occlusion.

[0052] 4. The process according to any one of the preceding items, wherein the semifluorinated alkane is a semifluorinated alkane of formula (I)

[0053] CF 3 (CF 2 )n(CH 2 )mCH 3 (I)

[0054] wherein n is an integer selected from 2 to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
densityaaaaaaaaaa
surface tensionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition comprising tacrolimus and a semifluorinated alkane for use in the treatment of ocular neovascularisation.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating ocular neovascularization, which comprises tacrolimus. Furthermore, the present invention relates to a method of treating ocular neovascularization comprising administering a composition comprising tacrolimus. Background technique [0002] Angiogenic eye disease is one of the most common causes of blindness worldwide. [0003] Angiogenesis is controlled by a homeostasis between pro-angiogenic and anti-angiogenic factors. Several conditions can affect the balance and lead to neovascularization. Ocular angiogenesis, especially in the retina and choroid, can lead to significant visual impairment. Diabetic retinopathy, neovascular age-related macular degeneration (AMD), retinopathy of prematurity, and retinal vascular occlusion are major causes of angiogenesis-related visual loss. [0004] Vascular endothelial growth factor (VEGF) is considered to be the most critical regulator of ocula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/436A61K31/02A61P27/02
CPCA61K31/02A61K31/436A61P27/02A61K2300/00A61K9/0048
Inventor 徐和平F·道岑贝格M·威特
Owner NOVALIQ GMBH